BPC-157: What the Research Says
Regulatory notice: BPC-157 is currently classified as an FDA Category 2 bulk drug substance. As of April 2026, licensed compounding pharmacies are not legally permitted to prepare or dispense it. PepScribe does not currently offer BPC-157 and has no confirmed timeline for availability. This page is for educational purposes only and does not constitute medical advice or an offer to sell any product.
On February 27, 2026, the U.S. Department of Health and Human Services announced an intent to reclassify certain peptides, potentially including BPC-157. This announcement has not been formally published in the Federal Register and carries no legal effect until it is. Do not interpret this page as confirmation that BPC-157's legal status has changed or that PepScribe will offer it in the future.
What is BPC-157?
BPC-157 stands for Body Protection Compound-157. It's a synthetic peptide consisting of 15 amino acids, derived from a protein naturally found in human gastric juice. The peptide was first characterized by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s, and the same research group has produced the majority of published literature on it over the past three decades.
Unlike most peptides that mimic a single hormone or receptor target, BPC-157 appears to operate through multiple biological pathways — which is part of why it's generated so much interest in both research and clinical communities. It is also notable for showing activity via both injection and oral routes in animal models, which is uncommon for peptide compounds.
How it works (proposed mechanisms)
Blood vessel formation
A 2006 study by Sikiric et al. in the Journal of Physiology Parisdemonstrated that BPC-157 promotes the formation of new blood vessels in damaged tissue in rat models. The effect was mediated through VEGF (vascular endothelial growth factor) upregulation, potentially improving nutrient delivery and accelerating the body's natural repair process.
GH receptor upregulation
Research published by Sikiric et al. (2014) in Current Pharmaceutical Design found that BPC-157 may upregulate growth hormone receptor expression in animal models, which could play a role in the tissue-repair effects observed in preclinical studies. The interaction with the GH/IGF-1 axis is an active area of investigation.
NO system modulation
A series of studies by Sikiric's group, reviewed in a 2016 paper in Current Pharmaceutical Design, demonstrated that BPC-157 interacts with the nitric oxide system in rat models. The peptide appears to counteract both NO-synthase inhibition and excess NO, suggesting a modulatory rather than unidirectional effect on blood flow and inflammation signaling.
Inflammation reduction
Multiple publications from the Zagreb group (1993–2020s) report anti-inflammatory activity through several pathways, including modulation of pro-inflammatory cytokines such as TNF-alpha and IL-6 in animal injury models. A 2010 review in Journal of Physiology Paris summarized the multi-pathway anti-inflammatory profile, though exact mechanisms are still being characterized.
These mechanisms are based on preclinical and animal research, primarily from a single research group. Human clinical trial data for BPC-157 remains limited. None of these mechanisms have been confirmed through large-scale, independent human trials.
What the research suggests
The published research on BPC-157 is predominantly from animal models conducted by the Sikiric group at the University of Zagreb. Human clinical trial data is limited. Here's what the preclinical evidence shows.
Tendon and ligament repair
A 2003 study in the Journal of Orthopaedic Research (Chang et al.) found that BPC-157 accelerated tendon-to-bone healing in a rat Achilles tendon model. A separate 2010 study by Krivic et al. in Journal of Orthopaedic Surgery and Research reported improved tendon healing outcomes compared to controls. These findings have not been replicated in human trials.
Gastrointestinal mucosal protection
Given its origin from gastric proteins, BPC-157 has been extensively studied for GI-protective effects. Sikiric et al. published a foundational study in 1993 in Journal of Physiology Parisshowing mucosal protection against ethanol and NSAID-induced damage in rat models. Subsequent publications (2012–2020) in Current Pharmaceutical Design expanded on cytoprotective effects across multiple GI injury models.
Muscle injury recovery
A 2010 study by Pevec et al. in the Journal of Physiology Paris reported improved muscle healing in rat crush-injury models treated with BPC-157. The proposed mechanism involves angiogenesis and growth factor modulation. A 2019 review in Current Pharmaceutical Design by Sikiric et al. summarized the preclinical muscle-repair data, but human data is still lacking.
Neuroprotective properties
Preclinical work by Sikiric et al. published in Current Neuropharmacology (2018) and Current Pharmaceutical Design (2020) reported neuroprotective effects in animal models of drug-induced neurotoxicity, including protection against dopaminergic damage. This area of research is early-stage and not well-characterized in humans.
Administration (research context)
In published research, BPC-157 has been studied via subcutaneous injection and oral capsule administration. Both routes have shown activity in animal models, though bioavailability and optimal dosing have not been established through human pharmacokinetic studies.
Dosing in research contexts varies widely across studies, typically ranging from microgram-level doses in animal models. There is no established human dosing protocol from regulatory-grade clinical trials.
This is research context, not prescribing guidance. PepScribe does not currently offer BPC-157 and this information should not be interpreted as a dosing recommendation.
Side effects & safety considerations
Honest assessment: the safety data on BPC-157 in humans is thin. Here's what exists.
Generally well-tolerated in research
In the available preclinical data, BPC-157 has shown a favorable safety profile in animal models across a range of doses. Toxicology studies published by the Zagreb group found no lethal dose (LD1) could be established in rodents, and no organ toxicity was observed at doses far exceeding therapeutic ranges in multiple studies spanning 1993–2020.
Limited human safety data
There are no large-scale, peer-reviewed human safety trials for BPC-157. Most safety inferences are drawn from animal models and anecdotal reports — which is an important limitation to acknowledge. A Phase I trial (NCT04465890) for ulcerative colitis was registered on ClinicalTrials.gov, but results have not been published in peer-reviewed literature as of April 2026.
Known considerations
- •Possible interactions with anticoagulants due to effects on angiogenesis and blood flow pathways
- •Individuals with active cancer should exercise caution given the pro-angiogenic properties observed in research
- •Pregnant or breastfeeding individuals should not use any peptide without direct physician guidance
Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice.
Legal status
BPC-157 was placed on the FDA's Category 2 list of bulk drug substances in September 2023. This means licensed compounding pharmacies in the United States cannot legally prepare or dispense it as of April 2026.
On February 27, 2026, the U.S. Department of Health and Human Services (under RFK Jr.) announced an intent to reclassify certain peptides, potentially including BPC-157. That announcement has not been formally published in the Federal Register and carries no legal effect until it is.
Gray-market “research chemical” vendors sell substances labeled as BPC-157, but these products are unregulated. They are not subject to pharmaceutical-grade quality controls, and their purity, potency, and identity cannot be verified by consumers.
While BPC-157 isn't available, these physician-prescribed options may support similar goals
Recovery, tissue support, and cellular repair — through legally available, pharmacy-compounded peptides prescribed by a licensed clinician.
Sermorelin
Growth hormone-releasing peptide. Supports recovery, sleep quality, and body composition through your body's own GH pathway. Physician-prescribed and shipped to your door.
Get started →NAD+
Supports cellular repair, DNA maintenance, and the energy metabolism processes that decline with age. Physician-prescribed NAD+ therapy delivered to your door.
Get started →Get notified when BPC-157 becomes available
Be the first to know when BPC-157 becomes available through PepScribe. We'll email you when BPC-157 becomes legally available through compounding pharmacies — no spam, no selling your data.
We're building the clinical and pharmacy infrastructure now so we can offer BPC-157 from day one of reclassification.
Deep dives on BPC-157
Research-backed articles covering specific topics in depth.